Intravitreal injection of Pegaptanib(Macugen) for chronic central serous chorioretinopathy

Intravitreal injection of Pegaptanib(Macugen) for chronic central serous chorioretinopathy - Pegaptanib for chronic central serous chorioretinopathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003931

Enrollment

Registered

2010-07-25

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic central serous chorioretinopathy

Interventions

To Evaluate the efficacy of 0.3 mg dose of Pegaptanib in the treatment of chronic central serous retinopathy (CSC).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)A history of persistent central serous chorioretinopathy present for at least 3 months. 2)Serous neurosensory detachment in the macula, and typical dye leakage pattern in fluorescein angiography. 3)Documented subfoveal fluid by OCT. 4)No signs of choroidal neovascularization. 5)The ability and willingness to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1)Prior treatment with laser or PDT. 2)Signs of choroidal neovascularization. 3)Intra ocular surgeries within 3 month prior to screening, in the study eye. 4)Previously vitrectomized eyes. 5)Past history of systemic disease such as: Diabetic retinopathy. Mild to severe heart failure (Class III or IV assessed by using the New York Heart Association Functional Classification (NYHA)), unstable angina, acute coronary syndrome, myocardial infarction, or ventricular tachycardia Clinically significant peripheral vascular disease (amputation or symptoms of claudication) Renal failure. Liver failure. Cerebral infarction within the preceding 12 months. 6)Previously received radiation therapy to the affected eye. 7)Severe allergic reactions to sodium fluorescein dye, indocyanine green dye or Pegaptanib. 8)Pregnancy or potential pregnancy. 9)Unwilling or unable to follow or comply with all study related procedures.

Design outcomes

Primary

Measure	Time frame
Proportion of subjects improved in best-corrected distance visual acuity (BCVA) at 24 weeks after initiation of pegaptanib.	—

Secondary

Measure	Time frame
1)Mean change in best corrected visual acuity (BCVA) from baseline at 24 weeks. 2)Proportion of subjects who lose less than 15 letters of BCVA from baseline at 24 weeks. 3)Anatomical change by OCT and fluorescein angiography.	—

Countries

Japan

Contacts

Public ContactAtsuro Uchida

Keio University School of Medicine Department of Ophthalmology

atsuro@tt.rim.or.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026